Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure

Second Department of Internal Medicine, Gifu University School of Medicine, Japan.

OBJECTIVES: This study sought to examine plasma levels of soluble Fas/APO-1 receptor (sFas), an inhibitor of apoptosis, and soluble Fas ligand (sFas-L), an inducer of apoptosis, and their relation to each other and to other clinical variables, such as New York Heart Association functional class, tumor necrosis factor (TNF) and interleukin-6 (IL-6) in congestive heart failure (CHF). BACKGROUND: It has been recently reported that apoptotic cell death occurs in myocytes of dogs with CHF. Hypoxia is frequently seen in advanced CHF and can stimulate Fas/APO-1 receptors (Fas) to induce apoptosis in cultured myocytes. Fas and Fas ligand (Fas-L) are cell-surface proteins and representative apoptosis-signaling molecules. Fas on the cell membrane induces apoptosis when it binds Fas-L or sFas-L. However, plasma sFas, a molecule lacking the transmembrane domain of Fas, blocks apoptosis by inhibiting binding between Fas and Fas-L or sFas-L on the cell membrane. At present, it is unknown whether plasma sFas-L and plasma sFas increase in the presence of cardiac disease. METHODS: The study included 70 patients (mean [+/-SEM] age 65 +/- 2 years, range 21 to 93) with chronic CHF (coronary artery disease in 28, dilated cardiomyopathy in 27, valvular heart disease in 15) and 62 age- and gender-matched normal control subjects. Plasma levels of sFas, sFas-L, TNF-alpha and IL-6 were measured by enzyme-linked immunosorbent assays using monoclonal anti-human antibodies. RESULTS: There was no significant difference in sFas-L levels between normal subjects and patients in functional classes I to IV; however, sFas increased with severity of functional classification, independent of the underlying disease. sFas levels were significantly higher even in patients in functional class II than in normal subjects and those in functional class I, and were highest in patients in functional class IV (normal subjects; 2.2 +/- 0.1 ng/ml; functional class I: 2.2 +/- 0.2 ng/ml; functional class II: 3.1 +/- 0.2 ng/ml; functional class III: 3.9 +/- 0.3 ng/ml; functional class IV: 5.1 +/- 0.6 ng/ml). Plasma sFas levels were significantly higher in patients with elevated pulmonary artery wedge pressure and a decresed cardiac index than in those with values in the normal range. In patients in functional class IV, there was no significant difference in plasma sFas levels between the survivors and non-survivors during 6-month follow-up. However, plasma levels of sFas tended to decrease in nine patients with clinical improvement (baseline sFas: 5.2 +/- 0.8 ng/ml; 6-month sFas: 4.3 +/- 0.5 ng/ml, p = 0.07) but were similar in patients with no change in functional class. TNF-alpha and IL-6 were increased significantly only in patients in functional class IV, as previously reported, but were not related to sFas. CONCLUSIONS: We found elevated levels of plasma sFas and no increase in plasma sFas-L in human CHF. The increase in sFas may play an important role in the pathophysiologic mechanisms of CHF.

This article has been cited by other articles:

				A. Niessner, P. J. Hohensinner, K. Rychli, S. Neuhold, G. Zorn, B. Richter, M. Hulsmann, R. Berger, D. Mortl, K. Huber, et al. Prognostic value of apoptosis markers in advanced heart failure patients Eur. Heart J., April 1, 2009; 30(7): 789 - 796. [Abstract] [Full Text] [PDF]

				H. Okada, G. Takemura, K.-i. Kosai, A. Tsujimoto, M. Esaki, T. Takahashi, S. Nagano, H. Kanamori, S. Miyata, Y. Li, et al. Combined therapy with cardioprotective cytokine administration and antiapoptotic gene transfer in postinfarction heart failure Am J Physiol Heart Circ Physiol, March 1, 2009; 296(3): H616 - H626. [Abstract] [Full Text] [PDF]

				C. P. Dahl, L. Gullestad, B. Fevang, A. M. Holm, L. Landro, L. E. Vinge, A. E. Fiane, W. J. Sandberg, K. Otterdal, S. S. Froland, et al. Increased expression of LIGHT/TNFSF14 and its receptors in experimental and clinical heart failure Eur J Heart Fail, April 1, 2008; 10(4): 352 - 359. [Abstract] [Full Text] [PDF]

				I. D. Laoutaris, A. Dritsas, M. D. Brown, A. Manginas, M. S. Kallistratos, D. Degiannis, A. Chaidaroglou, D. B. Panagiotakos, P. A. Alivizatos, and D. V. Cokkinos Immune response to inspiratory muscle training in patients with chronic heart failure European Journal of Cardiovascular Prevention & Rehabilitation, October 1, 2007; 14(5): 679 - 686. [Abstract] [Full Text] [PDF]

				L. M. Blanco-Colio, J. L. Martin-Ventura, E. de Teresa, C. Farsang, A. Gaw, G. Gensini, L. A. Leiter, A. Langer, P. Martineau, G. Hernandez, et al. Increased Soluble Fas Plasma Levels in Subjects at High Cardiovascular Risk: Atorvastatin on Inflammatory Markers (AIM) Study, a Substudy of ACTFAST Arterioscler Thromb Vasc Biol, January 1, 2007; 27(1): 168 - 174. [Abstract] [Full Text] [PDF]

				A. Trikas, C. Antoniades, G. Latsios, K. Vasiliadou, I. Karamitros, D. Tousoulis, C. Tentolouris, and C. Stefanadis Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure Eur J Heart Fail, December 1, 2006; 8(8): 804 - 809. [Abstract] [Full Text] [PDF]

				S. Philipp, I. Pagel, K. Hohnel, J. Lutz, J. Buttgereit, T. Langenickel, P. Hamet, R. Dietz, and R. Willenbrock Regulation of caspase 3 and Fas in pressure overload-induced left ventricular dysfunction Eur J Heart Fail, December 1, 2004; 6(7): 845 - 851. [Abstract] [Full Text] [PDF]

				Y. Li, G. Takemura, K.-i. Kosai, T. Takahashi, H. Okada, S. Miyata, K. Yuge, S. Nagano, M. Esaki, N. C. Khai, et al. Critical Roles for the Fas/Fas Ligand System in Postinfarction Ventricular Remodeling and Heart Failure Circ. Res., September 17, 2004; 95(6): 627 - 636. [Abstract] [Full Text] [PDF]

				J. Nitobe, S. Yamaguchi, M. Okuyama, N. Nozaki, M. Sata, T. Miyamoto, Y. Takeishi, I. Kubota, and H. Tomoike Reactive oxygen species regulate FLICE inhibitory protein (FLIP) and susceptibility to Fas-mediated apoptosis in cardiac myocytes Cardiovasc Res, January 1, 2003; 57(1): 119 - 128. [Abstract] [Full Text] [PDF]

				A. Yndestad, J. Kristian Damas, H. Geir Eiken, T. Holm, T. Haug, S. Simonsen, S. S. Froland, L. Gullestad, and P. Aukrust Increased gene expression of tumor necrosis factor superfamily ligands in peripheral blood mononuclear cells during chronic heart failure Cardiovasc Res, April 1, 2002; 54(1): 175 - 182. [Abstract] [Full Text] [PDF]

				M. Shimizu, K. Fukuo, S. Nagata, T. Suhara, M. Okuro, K. Fujii, Y. Higashino, M. Mogi, Y. Hatanaka, and T. Ogihara Increased plasma levels of the soluble form of fas ligand in patients with acute myocardial infarction and unstable angina pectoris J. Am. Coll. Cardiol., February 20, 2002; 39(4): 585 - 590. [Abstract] [Full Text] [PDF]

				S. Adamopoulos, J. Parissis, D. Karatzas, C. Kroupis, M. Georgiadis, G. Karavolias, J. Paraskevaidis, K. Koniavitou, A. J. S. Coats, and D. T. Kremastinos Physical training modulates proinflammatory cytokines and the soluble Fas/soluble Fasligand system in patients with chronic heart failure J. Am. Coll. Cardiol., February 20, 2002; 39(4): 653 - 663. [Abstract] [Full Text] [PDF]

				S. Adamopoulos, J. T. Parissis, and D. Th. Kremastinos A glossary of circulating cytokines in chronic heart failure Eur J Heart Fail, October 1, 2001; 3(5): 517 - 526. [Abstract] [Full Text] [PDF]

				G. Matute-Bello, W. C. Liles, C. W. Frevert, M. Nakamura, K. Ballman, C. Vathanaprida, P. A. Kiener, and T. R. Martin Recombinant human Fas ligand induces alveolar epithelial cell apoptosis and lung injury in rabbits Am J Physiol Lung Cell Mol Physiol, August 1, 2001; 281(2): L328 - L335. [Abstract] [Full Text] [PDF]

				D. Skudicky, A. Bergemann, K. Sliwa, G. Candy, and P. Sareli Beneficial Effects of Pentoxifylline in Patients With Idiopathic Dilated Cardiomyopathy Treated With Angiotensin-Converting Enzyme Inhibitors and Carvedilol : Results of a Randomized Study Circulation, February 27, 2001; 103(8): 1083 - 1088. [Abstract] [Full Text] [PDF]

				K. Fuse, M. Kodama, Y. Okura, M. Ito, S. Hirono, K. Kato, H. Hanawa, and Y. Aizawa Predictors of Disease Course in Patients With Acute Myocarditis Circulation, December 5, 2000; 102(23): 2829 - 2835. [Abstract] [Full Text] [PDF]

				B. Bozkurt Activation of cytokines as a mechanism of disease progression in heart failure Ann Rheum Dis, November 1, 2000; 59(90001): i90 - 93. [Full Text] [PDF]

				T. Imanishi, C. E. Murry, H. Reinecke, T. Hano, I. Nishio, W.C. Liles, L. Hofsta, K. Kim, K. D. O'Brien, S. M. Schwartz, et al. Cellular FLIP is expressed in cardiomyocytes and down-regulated in TUNEL-positive grafted cardiac tissues Cardiovasc Res, October 1, 2000; 48(1): 101 - 110. [Abstract] [Full Text] [PDF]

				P. M. Kang, A. Haunstetter, H. Aoki, A. Usheva, and S. Izumo Morphological and Molecular Characterization of Adult Cardiomyocyte Apoptosis During Hypoxia and Reoxygenation Circ. Res., July 21, 2000; 87(2): 118 - 125. [Abstract] [Full Text] [PDF]

				P. M. Kang and S. Izumo Apoptosis and Heart Failure : A Critical Review of the Literature Circ. Res., June 9, 2000; 86(11): 1107 - 1113. [Full Text] [PDF]

				C Berry and A.L Clark Catabolism in chronic heart failure Eur. Heart J., April 1, 2000; 21(7): 521 - 532. [PDF]

				K. C. Wollert, J. Heineke, J. Westermann, M. Ludde, B. Fiedler, W. Zierhut, D. Laurent, M. K. A. Bauer, K. Schulze-Osthoff, and H. Drexler The Cardiac Fas (APO-1/CD95) Receptor/Fas Ligand System : Relation to Diastolic Wall Stress in Volume-Overload Hypertrophy In Vivo and Activation of the Transcription Factor AP-1 in Cardiac Myocytes Circulation, March 14, 2000; 101(10): 1172 - 1178. [Abstract] [Full Text] [PDF]

				H. N. Sabbah Apoptotic cell death in heart failure Cardiovasc Res, February 1, 2000; 45(3): 704 - 712. [Full Text] [PDF]

				S.A. Cook and P.A. Poole-Wilson Cardiac myocyte apoptosis Eur. Heart J., November 2, 1999; 20(22): 1619 - 1629. [PDF]

				M. Kanoh, G. Takemura, J. Misao, Y. Hayakawa, T. Aoyama, K. Nishigaki, T. Noda, T. Fujiwara, K. Fukuda, S. Minatoguchi, et al. Significance of Myocytes With Positive DNA In Situ Nick End-Labeling (TUNEL) in Hearts With Dilated Cardiomyopathy : Not Apoptosis but DNA Repair Circulation, June 1, 1999; 99(21): 2757 - 2764. [Abstract] [Full Text] [PDF]

				S. A Doggrell and L. Brown Rat models of hypertension, cardiac hypertrophy and failure Cardiovasc Res, July 1, 1998; 39(1): 89 - 105. [Full Text] [PDF]

				A. Haunstetter and S. Izumo Apoptosis : Basic Mechanisms and Implications for Cardiovascular Disease Circ. Res., June 15, 1998; 82(11): 1111 - 1129. [Full Text] [PDF]